BRIDGEBIO PHARMA, INC.

(BBIO)
  Report
Real-time Estimate Cboe BZX  -  05/19 12:30:00 pm EDT
7.435 USD   +4.87%
05/18BRIDGEBIO PHARMA, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/18TRANSCRIPT : BridgeBio Pharma, Inc. Presents at Citi Biopharma VIRTUAL Co-Panel Day, May-18-2022 02:30 PM
CI
05/18BridgeBio Transaction Reflects Healthy Market For FDA Priority Review Vouchers
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BridgeBio to Study BBP-398 With Amgen's Lumakras in Solid Tumors

01/13/2022 | 08:16am EDT

By Colin Kellaher

BridgeBio Pharma Inc. on Thursday said it plans to evaluate its BBP-398 small-molecular inhibitor in combination with Amgen Inc.'s cancer drug Lumakras in patients with advanced solid tumors with the KRAS G12C mutation.

BridgeBio, a Palo Alto, Calif., biopharmaceutical company, said it will sponsor a Phase 1/2 study designed to evaluate the safety, tolerability and preliminary efficacy of the combination, while Amgen will provide a supply of Lumakras.

KRAS mutations occur in roughly 17% of malignant solid tumors. The U.S. Food and Drug Administration last year approved Lumakras as the first targeted treatment for patients with KRAS G12C-mutated locally advanced or metastatic nonsmall-cell lung cancer.

BridgeBio's BBP-398 is an inhibitor of SHP2, an oncoprotein overexpressed in a variety of cancer cell types inhibitor. The company is currently advancing a Phase 1 study of BBP-398 in patients with solid tumors driven by mutations in the MAPK signaling pathway, including RAS and receptor tyrosine kinase genes.

BridgeBio last year agreed to collaborate with Bristol Myers Squibb Co. to evaluate the combination of BBP-398 with Bristol's blockbuster cancer drug Opdivo in patients with advanced solid tumors with KRAS mutations.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

01-13-22 0816ET

Stocks mentioned in the article
ChangeLast1st jan.
AMGEN INC. -0.20% 243.42 Delayed Quote.8.44%
BRIDGEBIO PHARMA, INC. 5.92% 7.51 Delayed Quote.-57.49%
ON SEMICONDUCTOR CORPORATION 1.77% 56.86 Delayed Quote.-17.80%
All news about BRIDGEBIO PHARMA, INC.
05/18BRIDGEBIO PHARMA, INC. : Entry into a Material Definitive Agreement, Creation of a Direct ..
AQ
05/18TRANSCRIPT : BridgeBio Pharma, Inc. Presents at Citi Biopharma VIRTUAL Co-Panel Day, May-1..
CI
05/18BridgeBio Transaction Reflects Healthy Market For FDA Priority Review Vouchers
AQ
05/17BridgeBio Pharma to Participate in May Investor Events
GL
05/17BridgeBio Pharma to Participate in May Investor Events
AQ
05/16BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million ..
AQ
05/13BRIDGEBIO PHARMA, INC. : Entry into a Material Definitive Agreement, Financial Statements ..
AQ
05/13BridgeBio Pharma Sells Priority Review Right for Treatment of Rare Pediatric Disease fo..
MT
05/13BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million ..
GL
05/12BridgeBio Pharma, Bristol-Myers Squibb Agreement Should Make Investors Rethink Position..
MT
More news
Analyst Recommendations on BRIDGEBIO PHARMA, INC.
More recommendations
Financials (USD)
Sales 2022 51,6 M - -
Net income 2022 -560 M - -
Net Debt 2022 1 121 M - -
P/E ratio 2022 -1,83x
Yield 2022 -
Capitalization 1 047 M 1 047 M -
EV / Sales 2022 42,1x
EV / Sales 2023 32,9x
Nbr of Employees 577
Free-Float 64,1%
Chart BRIDGEBIO PHARMA, INC.
Duration : Period :
BridgeBio Pharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRIDGEBIO PHARMA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 7,09 $
Average target price 25,00 $
Spread / Average Target 253%
EPS Revisions
Managers and Directors
Neil Kumar Chief Executive Officer & Director
Brian C. Stephenson Chief Financial Officer & Secretary
Uma Sinha Chief Scientific Officer
Richard H. Scheller Director, Chairman-Research & Development
Christine E. Siu Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BRIDGEBIO PHARMA, INC.-57.49%1 047
JOHNSON & JOHNSON2.59%461 811
PFIZER, INC.-14.65%282 789
ABBVIE INC.12.58%269 361
ELI LILLY AND COMPANY6.87%265 718
ROCHE HOLDING AG-15.26%264 329